Telemetry Investments’s Acceleron Pharma XLRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-2,000
| Closed | -$344K | – | 213 |
|
|
2021
Q3 | $344K | Buy |
+2,000
| New | +$262K | 0.46% | 74 |
|
|
2018
Q3 | – | Sell |
-7,500
| Closed | -$364K | – | 161 |
|
|
2018
Q2 | $364K | Buy |
+7,500
| New | +$273K | 0.14% | 73 |
|
|
2018
Q1 | – | Sell |
-9,500
| Closed | -$403K | – | 182 |
|
|
2017
Q4 | $403K | Sell |
9,500
-16,110
| -63% | -$604K | 0.15% | 79 |
|
|
2017
Q3 | $956K | Sell |
25,610
-9,069
| -26% | -$315K | 0.34% | 47 |
|
|
2017
Q2 | $1.05M | Buy |
34,679
+6,709
| +24% | +$194K | 0.5% | 42 |
|
|
2017
Q1 | $740K | Sell |
27,970
-8,560
| -23% | -$226K | 0.33% | 46 |
|
|
2016
Q4 | $932K | Buy |
36,530
+24,530
| +204% | +$777K | 0.53% | 38 |
|
|
2016
Q3 | $434K | Sell |
12,000
-6,500
| -35% | -$215K | 0.27% | 53 |
|
|
2016
Q2 | $629K | Sell |
18,500
-20,000
| -52% | -$650K | 0.34% | 46 |
|
|
2016
Q1 | $1.02M | Buy |
38,500
+30,570
| +385% | +$889K | 0.3% | 44 |
|
|
2015
Q4 | $387K | Sell |
7,930
-46,770
| -86% | -$1.68M | 0.13% | 86 |
|
|
2015
Q3 | $1.36M | Buy |
54,700
+700
| +1% | +$21K | 0.58% | 47 |
|
|
2015
Q2 | $1.71M | Buy |
54,000
+34,500
| +177% | +$1.11M | 0.77% | 34 |
|
|
2015
Q1 | $742K | Buy |
19,500
+10,500
| +117% | +$418K | 0.41% | 50 |
|
|
2014
Q4 | $351K | Buy |
+9,000
| New | +$314K | 0.22% | 113 |
|
Telemetry Investments's XLRN Position: Q4 2021 in Review
Telemetry Investments sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 2,000 shares — an estimated $344K sold.
Telemetry Investments first reported a position in XLRN in Q4 2014 and held it in 15 quarters. The position peaked at $1.71M in Q2 2015. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.
- Telemetry Investments reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
- Telemetry Investments sold 2,000 Acceleron Pharma shares in Q4 2021, an estimated $344K.
- Telemetry Investments first reported a position in Acceleron Pharma in Q4 2014 and held it in 15 quarters.
- Telemetry Investments's Acceleron Pharma position peaked at $1.71M in Q2 2015.
- 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.
Based on Telemetry Investments's 13F filing for Q4 2021, filed 14 Feb 2022.